CSL Limited (ASX:CSL) Shares: Cost Cuts, Buyback and US ...
CSL closed at about A$186.30 on Friday, 28 November 2025, with shares down roughly 34% for the year and market cap near A$90 billion.
ts2.techCSL has been under pressure with a sustained decline in its share price over the past year, with recent reports showing it trading at multi-year lows and a sizable year-to-date drop. The latest news indicates ongoing concerns about profitability guidance, margin pressures, and strategic changes (including any demerger plans and cost cuts) that have reduced investor confidence.
Key points from recent coverage:
- The share price touched multi-year lows and has fallen roughly 50% from its highs over the last 12 months, highlighting a dramatic reversal in momentum.[7]
- Market commentary attributes much of the weakness to repeated guidance downgrades, weaker medium-term growth expectations, and questions about management’s forecast credibility after several resets.[1][2]
- Some analyses note that even after sharp falls, there is still debate among analysts about recovery timing, with target prices ranging widely and near-term catalysts needed to re-rate the stock.[3][1]
What this means for investors:
- If you’re evaluating CSL today, consider the trajectory of operating margins, the pace of any restructuring or cost-cutting benefits, and the potential impact of Seqirus strategy decisions or vaccine market dynamics on future revenue.
- Compare CSL’s valuation to peers and assess whether the current multiple already prices in a challenging medium-term outlook, or if there’s upside contingent on margin recovery and growth re-acceleration.
Illustrative snapshot (as reported in recent coverage):
- Price near levels not seen in years, with a roughly 40–50% decline over the last year depending on the measure, signaling material value destruction for long-term holders.[2][7]
- Analyst views are mixed, with some suggesting the stock could be attractively priced if margins recover and guidance re-stabilizes, while others warn that structural risks (vaccination demand, pipeline execution) remain salient.[1][3]
If you’d like, I can tailor a quick snapshot for your location (Miami, FL) with current ASX trading hours, or pull the most recent closing price and a short summary of the latest earnings/news to help you decide on any action. I can also create a simple chart showing the last 12–24 months of CSL prices if you want a visual sense of the decline.